Ion Beam Applications
Ion Beam Applications is a Belgium-based company focused on developing and marketing technologies and pharmaceutical products for the healthcare sector, specifically in cancer diagnosis and treatment. The company operates primarily through two segments: pharmaceuticals and equipment. The pharmaceuticals segment includes radiopharmaceuticals, while the equipment segment encompasses proton therapy systems, particle accelerators, and dosimetry solutions. IBA's proton therapy and accelerator business is a significant contributor to its revenues, providing precision cancer treatment using proton beams and cyclotrons for radioisotope production. Additionally, the dosimetry segment offers measurement and quality assurance tools for radiotherapy and medical imaging. IBA serves various markets, including Belgium, the United States, and other regions, while also engaging in sterilization and ionization applications.
7 past transactions
PanTera
Series A in 2024
PanTera focuses on the large-scale production of actinium-225, a promising radioisotope for targeted cancer therapies. The company aims to improve accessibility to personalized nuclear medicine treatments while ensuring sustainability through the recycling of materials in their production process.
Radcal
Acquisition in 2024
Radcal is a manufacturer of diagnostic X-ray imaging solutions focused on medical and healthcare applications. The company specializes in the development and provision of X-ray system instrumentation and related products, including ion chambers, solid-state sensors, current probes, and radiography accessories. By offering a diverse array of diagnostic measurement devices, Radcal aids healthcare professionals in ensuring minimal radiation exposure and achieving accurate diagnoses during medical treatments.
Hil Applied Medical
Corporate Round in 2016
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).
New Mexico Positron
Acquisition in 2005
New Mexico Positron manufactures and distributes Positron Emission Tomography (PET) tracers.
RadioMed Corporation
Acquisition in 2003
RadioMed Corporation, a developer of medical devices incorporating radioisotopes for inhibition of cellular proliferation.
Sotera Health
Acquisition in 1999
Sotera Health Company is a global provider of critical sterilization services and lab testing, ensuring the safety of medical devices, pharmaceuticals, and food products. It operates through three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics offers terminal sterilization and irradiation services using Ethylene Oxide (EO), Gamma, and Electron Beam (E-Beam) technologies. Nordion supplies Co-60 and gamma irradiators, essential for gamma sterilization. Nelson Labs provides microbiological and analytical chemistry testing for medical devices and pharmaceuticals. With a presence in the U.S. and internationally, Sotera Health's mission is to "Safeguard Global Health".
Signatur Biosciences
Signatur Biosciences, founded in 2022, is focused on advancing molecular diagnostics through a novel PCR testing platform. The company aims to make precision diagnostics more accessible by utilizing the molecular mechanisms of PCR to simplify the detection and interpretation of a comprehensive panel of RNA biomarkers into a single test. This innovative approach includes a smart kit that is compatible with existing machines and readily available reagents, allowing clinicians to seamlessly integrate the technology into their current clinical workflows and infrastructure.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.